. Author manuscript; available in PMC: 2022 May 10.

Published in final edited form as: J Alzheimers Dis. 2022;87(1):141–148. doi: 10.3233/JAD-215708

Table 1.

Baseline demographics (N=248)^*

Age (years)	72.78±4.80
Education (years)	16.33±2.45
Women, N (%)	127 (51.21%)
Race, Caucasian, N (%)	220 (88.71%)
APOE4, N	82 (33.47%)
MMSE (out of 30)	29.28±1.00
Depression, N (%)	23 (9.27%)
GDS (out of 15)	0.69±1.76
NPIQ (out of 36)	0.92±1.36
Follow-up time (years)	3.12±2.31

POMS
TMD	−4.74±8.61
Tension/Anxiety	32.83±3.87
Depression	32.52±2.29
Anger	36.49±2.11
Vigor	58.91±9.74
Fatigue	32.36±4.48
Confusion	38.08±3.78
Biomarker status (%)	+	−
Aβ₄₂/Aβ₄₀	95 (38.31%)	153 (61.69%)
t-Tau/Aβ₄₂	84 (33.87%)	164 (66.13%)
p-Tau/Aβ₄₂	79 (31.85%)	169 (68.15%)

Abbreviations: APOE4 = Apolipoprotein E ε4 allele; MMSE = Mini-Mental State Examination; POMS = Profile of Mood States; TMD = Total Mood Disturbance; GDS = Geriatric Depression Scale; NPIQ = Neuropsychiatric Inventory Questionnaire

Mean ± Standard Deviation or count (percentage)